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Abstract
Summary Numerous observational studies suggest that hypnotics increase the risk of fractures, and long-acting hypnotics are
suggested to be especially harmful. This study showed that the highest risk of fracture was found before start of treatment and
remained after end of therapy, suggesting that the increased risk during treatment is influenced by other factors, such as
underlying disease.
Introduction The purpose of this study was to evaluate associations between the use of short-acting and long-acting hypnotics
and the risk of fracture.
Methods Four cohorts were formed from all individuals living in Sweden aged ≥ 50 years in 2005 (n = 3,341,706). In the first
cohort, individuals prescribed long-acting propiomazine (n = 233,609) were matched 1:1 with controls. In the second cohort,
individuals prescribed short-acting z-drugs (zopiclone, zolpidem, and zaleplon, n = 591,136) were matched 1:1 with controls.
The third and fourth cohorts consisted of full sibling pairs with discordant propiomazine (n = 83,594) and z-drug (n = 153,314)
use, respectively.
Results The risk of fracture was greatest among users of hypnotics in the 90 days before the initiation of treatment, both for
propiomazine (odds ratio [OR], 2.52; 95% confidence interval [CI], 2.28–2.79) and z-drugs (OR, 4.10; 95% CI, 3.86–4.35)
compared with that in matched controls. Furthermore, this risk was significantly reduced after the initiation of treatment with
propiomazine (OR, 1.42; 95%CI, 1.27–1.60) and z-drugs (OR, 1.67; 95%CI, 1.56–1.80) and remained the first year following the
last prescribed dose both for propiomazine (OR, 1.28, 95%CI, 1.21–1.36) and z-drugs (OR, 1.19, 95%CI, 1.16–1.23). The pattern
was similar in the sibling cohorts, with the greatest risk of fracture seen in the 90 days before treatmentwith hypnoticswas initiated.
Conclusion The use of short-acting and long-acting hypnotics is associated with an increased risk of fracture. This risk was
highest before initiation of treatment and remained after end of therapy. The results suggest that the increased risk during
treatment is influenced by other factors such as underlying disease.
Keywords Fractures . Hypnotics
Introduction
The ability to sleep decreases while insomnia increases in
older individuals [1, 2]. These disturbances may result from
normal age-related physiological changes, or they may be
secondary to a variety of factors, such as underlying disease.
Various drugs are commonly used to improve sleep distur-
bance. According to national registers, 33% of the population
in Sweden aged at least 50 years has received at least one
prescription for zopiclone, zolpidem, or zaleplon (z-drugs)
[3], the drugs used most commonly for insomnia. However,
according to recent practical guidelines of the American
Academy of Sleep Medicine, the evidence for z-drugs and
other drugs for sleeping disorders is weak [4]. Furthermore,
the use of z-drugs and other hypnotics has been associated
with unfavorable side effects, including drowsiness, gait im-
pairment, reduced cognitive function [5], and an increased risk
of fracture [6, 7]. Perhaps the most serious side effect
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associated with the use of hypnotics is hip fracture [8], as
many of the patients lose independence and 25% die within
the first year after the event [9].
Based on the risk of side effects, short-acting z-drugs are
generally recommended over more long-acting hypnotics,
such as benzodiazepines and neuroleptics [4, 10]. Z-drugs
are also suggested to result in a more natural sleep pattern
[11] and lack of tolerance and dependency compared with
most other hypnotics [12]. However, to our knowledge, the
risk of side effects associated with short-acting and long-
acting hypnotics has not been compared in a randomized con-
trolled study or large observational study. The association be-
tween hypnotics and fractures has also not been evaluated
before therapy is started and after it is ended. The purpose of
the present study was to compare the risks of fracture associ-
ated with the use of z-drugs and the long-acting hypnotic
propiomazine. Another aim was to critically evaluate the as-
sociation between hypnotic use and fracture.
Materials and methods
Data sources
This study was conducted with data from three Swedish data-
bases: the Prescribed Drug Registry, the National Patient
Registry (NPR), and the Cause of Death Registry. The
Prescribed Drug Registry consists of records for all drug pre-
scriptions filled at Swedish pharmacies since July 2005. The
NPR includes records of all diagnoses made in inpatient care
settings since 1987 and specialist outpatient care settings since
2001. The Cause of Death Registry contains data on causes
and dates of death for all Swedish residents. These data were
linked by Statistics Sweden using unique 10-digit civil regis-
tration numbers, which all Swedish residents have. Statistics
Sweden also anonymized the data before receipt by the prin-
cipal investigator (PN) and provided access to kinship and
socioeconomic data, such as education, income, and early
disability pension receipt. Diagnoses in the study cohorts were
tracked in the NPR using International Classification of
Diseases, 10th revision (ICD-10) codes (available since
1997). The present study was approved by the ethical com-
mittee of Umeå university, by the National Board of Health
and Welfare and by Statistics Sweden.
Study cohorts
All persons aged ≥ 50 years on 31 December 2005 (n =
3,341,706) were considered for inclusion. We excluded indi-
viduals who filled prescriptions for propiomazine (n =
140,602, 4.3%) or z-drugs (n = 477,868, 14.3%) before 1
January 2007 to increase the likelihood that therapy began
on the first recorded prescription date (data on prescriptions
prior to July 2005 were unavailable). Thus, persons who filled
prescriptions for propiomazine (n = 239,253, 7.2%) or z-drugs
(n = 613,306, 18.4%) at least once between 1 January 2007
and 31 December 2016 were considered to be users. After
excluding individuals with suspected inaccurate data, such
as a fracture or drug dispensation recorded after a person’s
date of death, 237,396 propiomazine users and 604,457 z-
drug users remained. Each user was matched with a non-
user from the rest of the cohort based on birth year, birth
month, sex, and Swedish or non-Swedish citizenship. Non-
users who died before the corresponding users were dispensed
their last doses of propiomazine or z-drugs were excluded and
replaced with other non-users from the rest of the cohort.
Unmatched individuals were excluded. This process yielded
233,609 propiomazine user/non-user pairs and 591,136 z-
drug user/non-user pairs. The third and fourth cohorts
consisted of all full sibling pairs from the total cohort with
discordant propiomazine (n = 83,594) and z-drug use (n =
153,314), respectively. The baseline date for each pair was
the date of treatment initiation. Sibling pairs in which the
drug-naïve sibling died before baseline were excluded. The
purpose of the subcohorts of siblings was to adjust for poten-
tial uncontrolled confounding due to familial and genetic fac-
tors that would not be captured in medical records.
Outcomes
The main study outcome was fracture (ICD-10 codes S22–
S82, excluding S62 [fracture of the hand]). The Swedish NPR
does not differentiate between new diagnoses and follow-up
examination data. To avoid counting the same fracture more
than once, only the first and last fractures in each individual
were analyzed, and these events had to be separated by at least
365 days for the second diagnosis to be included. In sensitivity
analyses, we also examined the secondary outcomes of hip
fracture (ICD-10 code S72), stroke (ICD-10 codes I61–I64),
and dementia (ICD-10 codes F00, F01, F039). NPR data have
been validated in detail, with positive predictive values
(PPVs) of 85–95% [13–15]. Notably, the PPV for hip fracture
in this register exceeds 95% [16].
Statistical analysis
Baseline characteristics are presented as means and standard
deviations, unless indicated otherwise. The baseline for each
matched case-control pair was set as the date on which the
user filled his or her first prescription.
To test whether the association between propiomazine or z-
drug use and the risk of fracture diagnosis was time depen-
dent, we evaluated Schoenfeld residuals using the estat phtest
command in the Stata software (version 12.1; StataCorp LP,
College Station, TX, USA). After determining that it was, we
used flexible parametric models, which unlike Cox regression
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models allow the inclusion of time-dependent covariates, for
survival analyses. Retrospective and prospective fractures
were analyzed independently using three degrees of freedom
and knots at default positions [17]. The analyses were condi-
tional, and thus adjusted for sex, age, and citizenship, but no
other adjusting variable was used.
To investigate the magnitude of the association between
drug use and fracture risk, conditional logistic regression
models for six time frames were used. Associations were an-
alyzed during days 1–90, 91–181, and 182–365 before and
after the initiation of therapy. In each analysis, each pair in
which a participant had a fracture or died in any time frame
closer to the baseline date was excluded. Ninety days after the
last prescription was filled, users and corresponding controls
were excluded from further analyses. Finally, if not censored
before, individuals were censored on 31 December 2016. The
Table 1 Baseline characteristics
of the propiomazine study cohort Propiomazine
users n = 233,609
Propiomazine
non-users n = 233,609
P value
Age 69.2 ± 9.9 69.2 ± 9.9
Civil status < 0.001
Married 126,872 (54.3%) 139,114 (59.5%)
Not married 29,080 (12.4%) 27,419 (11.7%)
Divorced 50,577 (21.7%) 38,827 (16.6%)
Widow/widower 27,148 (11.6%) 27,148 (11.6%)
Missing data 268 (0.1%) 1024 (0.4%)
Education < 0.001
< 9 years Elementary school 37,936 (19.9%) 39,078 (20.6%)
9 years Elementary school 19,958 (10.4%) 18,969 (10.0%)
2 years Senior High school 62,156 (32.5%) 57,273 (30.2%)
> 2 years Senior High school 21,045 (11.0%) 22,089 (11.7%)
Post-secondary school 49,912 (26.1%) 52,145 (27.5%)
Missing data 42,602 (18.2%) 44,055 (18.9%)
Early retirement pension 44,731 (19.2%) 26,801 (11.5%) < 0.001
Diagnoses at baseline
Myocardial infarction 13,396 (5.7%) 9792 (4.2%) < 0.001
Angina pectoris 21,024 (9.0%) 15,334 (6.6%) < 0.001
Stroke 13,024 (5.6%) 8887 (3.8%) < 0.001
Diabetes mellitus or diabetes drugs 29,749 (12.7%) 24,151 (10.3%) < 0.001
Traumatic brain injury 11,302 (4.8%) 7253 (3.1%) < 0.001
Cancer 51,835 (22.2%) 37,122 (15.9%) < 0.001
Dementia or dementia drugs 7580 (3.2%) 4660 (2.0%) < 0.001
Depression or antidepressants 99,195 (42.5%) 38,957 (16.7%) < 0.001
Bipolar disease 3381 (1.4%) 659 (0.3%) < 0.001
Alcoholic intoxication 12,524 (5.4%) 2547 (1.1%) < 0.001
Opioid intoxication 967 (0.4%) 193 (0.1%) < 0.001
Psychosis 1028 (0.4%) 323 (0.1%) < 0.001
Renal failure 2058 (0.9%) 892 (0.4%) < 0.001
Chronic obstructive pulmonary disease 10,602 (4.5%) 4837 (2.1%) < 0.001
Rheumatoid arthritis 4450 (1.9%) 3582 (1.5%) < 0.001
Chrohn’s disease 1375 (0.6%) 967 (0.4%) < 0.001
Colitis 2099 (0.9%) 1612 (0.7%) < 0.001
Fracture 36,105 (15.5%) 28,750 (12.3%) < 0.001
Drugs prescribed at least once
Benzodiazepines 69,002 (29.5%) 25,943 (11.1%) < 0.001
Glucocorticoids 55,235 (23.6%) 35,757 (15.3%) < 0.001
Bisphosphonates 14,023 (6.0%) 10,400 (4.5%) < 0.001
Levothyroxin 24,983 (10.7%) 19,922 (8.5%) < 0.001
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clogit command in the Stata software was used to fit maxi-
mum likelihood (fixed-effect) models to estimate odds ratios
with the dichotomous dependent variable of interest, i.e.,
propiomazine or z-drug use. The likelihood was then calcu-
lated relative to each group, i.e., conditional likelihood was
used. The first model was unadjusted, although adjusted for
age, sex, and citizenship by design. The second model was
adjusted for civil status (four categories), education (five cat-
egories), early retirement pension receipt, 17 diagnoses at
baseline (all diagnoses listed in Tables 1 and 2, except
fracture), and baseline use of four drugs. Associations in the
year before baseline were adjusted for differences estimated at
1 year before baseline. Data from the sibling cohorts were
analyzed in a similar fashion, but only fully adjusted models
are presented. In the total matched cohorts, separate analyses
were performed according to subgroups defined by sex, age
group, depression diagnosis, use of certain medications, and
receipt of one or several prescriptions for propiomazine or z-
Table 2 Baseline characteristics
of the zopiclone/zolpidem/
zaleplon study cohort
Z users n = 591,136 Z non-users n = 591,136 P value
Age 72.1 ± 10.4 72.1 ± 10.4
Civil status < 0.001
Married 338,370 (57.2%) 346,646 (58.6%)
Not married 61,674 (10.4%) 64,372 (10.9%)
Divorced 106,265 (18.0%) 89,622 (15.2%)
Widow/widower 83,741 (14.2%) 88,218 (14.9%)
Missing data 792 (0.1%) 2112 (0.4%)
Education < 0.001
< 9 years Elementary school 100,218 (22.7%) 104,552 (23.9%)
9 years Elementary school 41,970 (9.5%) 40,555 (9.3%)
2 years Senior High school 135,816 (30.8%) 130,977 (29.9%)
>2 years Senior High school 47,858 (10.9%) 49,747 (11.4%)
Post-Secondary school 114,728 (26.0%) 112,074 (25.6%)
Missing data 150,547 (25.5%) 153,232 (25.9%)
Early retirement pension 79,674 (13.5%) 52,192 (8.9%) < 0.001
Diagnoses at baseline
Myocardial infarction 40,789 (6.9%) 26,589 (4.5%) < 0.001
Angina pectoris 58,398 (9.9%) 40,031 (6.8%) < 0.001
Stroke 42,676 (7.2%) 24,891 (4.2%) < 0.001
Diabetes mellitus or diabetes drugs 82,255 (13.9%) 61,361 (10.4%) < 0.001
Traumatic brain injury 24,790 (4.2%) 17,841 (3.0%) < 0.001
Cancer 150,617 (25.5%) 96,394 (16.3%) < 0.001
Dementia or dementia drugs 28,840 (4.9%) 13,799 (2.3%) < 0.001
Depression or antidepressants 176,432 (29.8%) 74,690 (12.6%) < 0.001
Bipolar disease 3381 (1.4%) 659 (0.3%) < 0.001
Alcoholic intoxication 14,770 (2.5%) 5363 (0.9%) < 0.001
Opioid intoxication 1088 (0.2%) 278 (0.05%) < 0.001
Psychosis 1688 (0.3%) 620 (0.1%) < 0.001
Renal failure 6203 (1.0%) 2121 (0.4%) < 0.001
Chronic obstructive pulmonary disease 26,227 (4.4%) 10,974 (1.9%) < 0.001
Rheumatoid arthritis 11,602 (2.0%) 8596 (1.5%) < 0.001
Chrohn’s disease 3087 (0.5%) 2025 (0.3%) < 0.001
Colitis 4835 (0.8%) 3492 (0.6%) < 0.001
Fracture 98,609 (16.7%) 77,028 (13.0%) < 0.001
Drugs prescribed at least once
Benzodiazepines 121,807 (20.6%) 49,236 (8.3%) < 0.001
Glucocorticoids 144,844 (24.5%) 84,448 (14.3%) < 0.001
Bisphosphonates 39,009 (6.6%) 27,654 (4.7%) < 0.001
Levothyroxin 62,159 (10.5%) 50,290 (8.5%) < 0.001
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drugs. Unadjusted estimates are presented for all intervals in
the subgroup analyses when the estimate for at least one in-
terval was found to be unstable in fully adjusted models. The
Stata software (versions 12.1 and 15.1) and SPSS software
(version 23; IBM, Armonk, NY, USA) were used to fit the
statistical models and to illustrate the results graphically. P
values < 0.05 were considered to be significant.
Results
Baseline characteristics
The characteristics of the matched cohorts based on
propiomazine and z-drug use are presented in Tables 1 and
2, respectively. The mean ages at baseline in the propiomazine
and z-drug cohorts were 69 and 72 years, respectively. In both
cohorts, all baseline characteristics differed significantly be-
tween users and non-users. The greatest differences at baseline
included higher prevalences of benzodiazepine use, glucocor-
ticoid use, and depression or use of antidepressant drugs in
propiomazine and z-drug users compared with non-users.
Fracture risk
The risks of fracture in the propiomazine cohort before and
after the initiation of therapy are presented in Fig. 1. The risk
associated with propiomazine use was greatest in the 90 days
preceding the initiation of therapy (odds ratio [OR], 2.94; 95%
confidence interval [CI], 2.73–3.16; Table 3). This risk was
somewhat attenuated after adjustment for confounders (OR,
2.52; 95%CI, 2.28–2.79). In the first 90 days after initiation of
therapy, this risk was reduced by more than half (OR, 1.42;
95% CI, 1.27–1.60) and the risk remained constant thereafter
(Figs. 1 and 2, Table 3). The pattern was similar for hip frac-
ture, with the greatest risk seen in the 90 days before the
initiation of propiomazine use (Table 3). The pattern of greater
fracture risk before than after the initiation of therapy was
consistent in all subgroups defined according to age, certain
diagnoses, and one or several prescriptions for propiomazine
(Table 3). The risk of fracture after termination of therapy
could be analyzed in 182,589 pairs, where one individual in
each pair from the original cohort had previous use of
propiomazine (Fig. 3). The first year after last prescribed dose,
previous users still had an increased risk of fracture (OR, 1.28,
95% CI, 1.21–1.36), after adjustment for all confounders.
The risks of fracture in the z-drug cohort before and after
the initiation of therapy are presented in Fig. 2. As in the
propiomazine cohort, the risk associated with the use of z-
drugs was greatest in the 90 days preceding therapy initiation
(OR, 4.10; 95% CI, 3.86–4.35; Table 4). This increased risk
was more than halved after the initiation of therapy (OR, 1.67;
95% CI, 1.56–1.80; Table 4), and the risk declined further
with increasing follow-up time (Table 4). The pattern was
similar for the outcome of hip fracture, with the greatest risk
seen before the initiation of z-drug use (Table 4). The pattern
of greater risk before than after the initiation of therapy was
consistent in all subgroups defined according to age, certain
diagnoses, and one or several prescriptions for z-drugs
(Table 4). The risk of fracture after termination of therapy
could be analyzed in 370,213 pairs, where one individual in
each pair from the original cohort had previous use of z-drugs
(Fig. 4). The first year after last prescribed dose, previous
users still had an increased risk of fracture (OR, 1.20, 95%
CI, 1.15–1.26), after adjustment for all confounders. Finally,
individuals on the higher strength of the respective z-drug
(10 mg, n = 73,615) had a lower risk of fracture than individ-
uals on a lower strength (n = 517,521) both the year before
Fig. 1 Associations between
propiomazine treatment initiation
and fracture. Flexible parametric
models for the matched cohort of
propiomazine users and controls
(n = 467,218). Conditional
analyses were performed using
four degrees of freedom and knots
at default positions. The gray area
represents the 95% confidence
interval
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(OR, 0.82, 95% CI, 0.77–0.88) and after initiation of therapy
(OR, 0.90, 95% CI, 0.84–0.97), after adjustment of all
confounders.
Sensitivity analysis results
The risk patterns associated with fracture in propiomazine
users and z-drug users were tested in several sensitivity anal-
yses. In the first analysis, the risk was investigated in the two
subcohorts of sibling pairs with discordant drug use. The pat-
terns associated with drug use in the sibling cohorts were
similar to those in the main cohort, with the greatest risk of
fracture seen before treatment was initiated (Tables 3 and 4).
Finally, we investigated the risks of stroke and dementia as-
sociated with use of the drugs of interest. The patterns were
similar to those observed for the outcome of fracture, with the
greatest risk seen before the initiation of treatment with
propiomazine and z-drugs (Tables 3 and 4).
Discussion
This study showed that the initiation of treatment with
propiomazine and z-drugs is associated strongly with an in-
creased risk of fracture. However, this risk was even higher
before initiation of therapy. The strength of associations in-
creased from 1 year before the baseline date, peaked close to
this date, and then fell after the initiation of treatment with
hypnotics. The associations had similar patterns in siblings,
women and men, different age groups, and different subgroups
Fig. 2 Associations between z-
drug treatment initiation and
fracture. Flexible parametric
models for the matched cohort of
z-drug users and controls (n =
1,182,272). Conditional analyses
were performed using five de-
grees of freedom and knots at de-
fault positions. The gray area
represents the 95% confidence
interval
Fig. 3 Associations between
previous propiomazine use and
fracture after end of therapy.
Kaplan-Meier curve for the out-
come of fracture in previous users
of propriomazine and corre-
sponding controls. Cumulative
incidence of fracture and 95%
confidence intervals (95% CI) are
presented
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1990 Osteoporos Int (2019) 30:1983–1993
defined according to certain diagnoses and use of certain drugs.
It is also of interest that the association remained in the first year
after therapy was ended for both propriomazine and the z-
drugs. Finally, the patterns were similar in sensitivity analyses
for the outcomes of stroke and dementia.
The associations after the initiation of therapy between
hypnotic use and fracture confirm the results of previous ob-
servational studies of the use of other neuroleptics [18–21]
and those of meta-analysis of z-drug use [6, 7]. However, to
our knowledge, no previous large observational study has
critically evaluated this association by also analyzing the risk
of fracture before the initiation of therapy and after end of
therapy. In our study cohorts, the risk of fracture was greatest
in the last 3 months before the initiation of treatment. This risk
was significantly higher than after the initiation of therapy, and
the pattern was true for all four cohorts analyzed. This was
especially true for the short-acting z-drugs, and the results
strongly suggest that the association found between hypnotic
use and fracture after initiation of therapy is not causal. Thus,
the greater risk of fracture before beginning treatment with
hypnotics probably explains the greater risk of fracture after
treatment initiation. This explanation is supported by the fact
that the associations remained after therapy with hypnotics
was ended. This is also supported by the greater prevalence
of all considered diseases in users of hypnotics. Yet, disease
severity is not indicated in the registry data used, which likely
contribute to residual confounding in the present study, as in
other observational studies. Finally, register studies cannot
measure factors such as general frailty, which increases the
risks of many outcomes, including fracture [22]. Our results
may represent real-life situations in which individuals have
conditions that influence sleep, according to our results a frac-
ture, and are prescribed hypnotics to improve accompanying
sleep disorders because of fracture occurrence. These patients
would have a greater risk of a new fracture, not necessarily
because of hypnotic use, but due to existing conditions that
increase the risks of falling and fracture. During treatment
with hypnotics, the underlying condition may improve and
the patients’ fracture risk is reduced compared to before ther-
apy was started. Another less likely explanation for the main
results is that different underlying factors influence the risk of
fracture before and after the initiation of treatment with hyp-
notics. If so, it would still be difficult to explain the remaining
increased risk after therapy is terminated, and the fact that a
higher strength of z-drugs was associated with lower risk of
fracture. It is of interest that we found a quite similar associ-
ation between antidepressants and fractures in a recent study
[23], drugs that previously also have been associated with an
increased risk of fractures [24, 25].
We further evaluated the causality of the association be-
tween hypnotic use and fracture in sensitivity analyses. In
particular, we evaluated the associations between hypnotic
use and the outcomes of stroke and dementia. In these analy-
ses, the patterns of association with hypnotic use were similar
to that seen for fracture, with the greatest risk observed before
the start of treatment. With respect to causality, hypnotic use
could theoretically increase the risk of stroke [26, 27], al-
though the results of the present study strongly suggest that
the association after the initiation of therapy represents resid-
ual confounding and reverse causality. Irrespectively, hypnot-
ic use cannot cause dementia within weeks after the initiation
of treatment. Instead, undiagnosed early dementia was likely
present in this cohort in the period before the initiation of
therapy [28]; this condition is often accompanied by anxiety
and depression, resulting in decreased sleep quality.
Despite the obvious pitfalls associated with the evaluation
and comparison of side effects of different drugs using obser-
vational data, cohort studies are often used for this purpose. In
Fig. 4 Associations between
previous z-drug use and fracture
after end of therapy. Kaplan-
Meier curve for the outcome of
fracture in previous users of z-
drugs and corresponding controls.
Cumulative incidence and 95%
confidence intervals (95% CI) are
presented
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a well-cited study of the risks of side effects of different types
of antidepressants [29], selective serotonin inhibitors were as-
sociated with greater risks of falls and other side effects com-
pared with tricyclic antidepressants. Another aim of the pres-
ent study was to critically evaluate any difference in fracture
risk after the initiation of propiomazine and z-drug use. If only
the risk after the initiation of therapy was assessed, z-drug use
would be associated with slightly greater risks not only of
fracture, but also of stroke and dementia. However, examina-
tion of the associations also before treatment initiation shows
that the associations after baseline likely reflect the increased
risk before the initiation of therapy, and thus residual con-
founding and reverse causality.
Several limitations of this study should be considered.
The registry-based nature of the study resulted in the lack
of some important information, such as whether and how
often patients took the medications they had obtained at
pharmacies. In addition, no information was available on
confounders such as physical activity, eating habit, weight,
or smoking habit. Chronic obstructive pulmonary disease
data were available as a surrogate for smoking, but this
surrogate is inexact. Alcohol intoxication data were avail-
able as a surrogate for excessive alcohol use, but this surro-
gate is also inexact. Information was also lacking for some
other drugs of potential interest, such as benzodiazepines,
neuroleptics, histamine H1 blockers, melatonin, and anti-
epileptics. Although access to data on more confounders
and more accurate estimation thereof would be of interest,
such differences would not likely have changed the results
of this study, as the risk of fracture was compared before and
after the initiation of treatment. The strengths of the present
study include the examination of a nationwide cohort and
the lack of data loss during follow-up, both of which in-
crease the external validity of the results.
In conclusion, this study showed that use of hypnotics is
associated with a greater risk of fracture after the age of
50 years in the Swedish population. However, this increased
risk is not likely to be causal, as the risk of fracture was greater
before than after the initiation of treatment and remained sim-
ilar after end of therapy. Given these results, similar investi-
gation of reported associations between the use of other drugs
and fracture, such neuroleptics other than propiomazine,
would be of interest. Finally, the results of the present study
emphasize the importance of not making inferences based on
observational data.
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